Genovis receives order worth about SEK 13 million
Genovis has received an order for SmartEnzymes that will be used in the manufacturing process for a biological drug. This is a new application for the company’s products. The order is the result of a favorable outcome from the evaluation study that was conducted at a global biopharma company in early 2019. The customer intends to use Genovis’ enzyme for production of a drug candidate in a phase 1 clinical study.Since the order relates to production of medications for a phase 1 clinical study, the outcome of this study could represent potential revenue flows moving forward. Exactly when